Pet Pharm Biotech Co., Ltd. (TPEX:7762)
Taiwan
· Delayed Price · Currency is TWD 60.10
-2.50 (-3.99%)
At close: Mar 9, 2026
Pet Pharm Biotech Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Cash & Equivalents | 321.49 | 181.79 | 168.49 | 16.76 |
| Cash & Short-Term Investments | 571.69 | 181.79 | 168.49 | 16.76 |
| Cash Growth | 3311.85% | 7.89% | 905.52% | - |
| Receivables | 41.59 | 33.78 | 31.24 | 20.91 |
| Inventory | 9.24 | 13.68 | 10.8 | 5.81 |
| Prepaid Expenses | 2.84 | 2.12 | 2.61 | - |
| Other Current Assets | 4.36 | 210.57 | 141.28 | 54.84 |
| Total Current Assets | 629.73 | 441.93 | 354.4 | 98.31 |
| Property, Plant & Equipment | 343.78 | 290.2 | 92.45 | 84.57 |
| Other Intangible Assets | 8.19 | 9.08 | 4.05 | 5.08 |
| Long-Term Deferred Tax Assets | 2.09 | 2.09 | - | - |
| Other Long-Term Assets | 120.78 | 16.76 | 36.67 | 3.93 |
| Total Assets | 1,105 | 760.06 | 487.58 | 191.89 |
| Accounts Payable | 1.48 | 7.92 | 4.81 | 2.91 |
| Current Portion of Long-Term Debt | 100 | 100 | - | - |
| Current Portion of Leases | 8.04 | 6.42 | 6.57 | 4.58 |
| Current Unearned Revenue | 3.96 | 4.31 | 3.94 | 3.09 |
| Other Current Liabilities | 29.69 | 21.41 | 16.99 | 8.88 |
| Total Current Liabilities | 143.17 | 140.05 | 32.31 | 19.46 |
| Long-Term Leases | 65.99 | 37.46 | 41.63 | 37.94 |
| Total Liabilities | 209.53 | 177.52 | 73.94 | 57.4 |
| Common Stock | 505.29 | 405.29 | 371.9 | 251.9 |
| Additional Paid-In Capital | 368.72 | 78.72 | 150.01 | - |
| Retained Earnings | 9.98 | 14.51 | -108.27 | -117.42 |
| Comprehensive Income & Other | 11.03 | 84.03 | - | - |
| Shareholders' Equity | 895.03 | 582.54 | 413.64 | 134.48 |
| Total Liabilities & Equity | 1,105 | 760.06 | 487.58 | 191.89 |
| Total Debt | 174.02 | 143.88 | 48.2 | 42.52 |
| Net Cash (Debt) | 397.67 | 37.91 | 120.29 | -25.77 |
| Net Cash Growth | - | -68.49% | - | - |
| Net Cash Per Share | 8.57 | 0.93 | 4.05 | -1.07 |
| Filing Date Shares Outstanding | 51.21 | 41.07 | 29.73 | 24.13 |
| Total Common Shares Outstanding | 51.21 | 41.07 | 29.73 | 24.13 |
| Working Capital | 486.56 | 301.88 | 322.1 | 78.85 |
| Book Value Per Share | 17.48 | 14.18 | 13.92 | 5.57 |
| Tangible Book Value | 886.84 | 573.47 | 409.59 | 129.4 |
| Tangible Book Value Per Share | 17.32 | 13.96 | 13.78 | 5.36 |
| Land | 172.41 | 172.41 | - | - |
| Machinery | 119.59 | 93.4 | 80.44 | - |
| Construction In Progress | 7.93 | 14.59 | - | - |
| Leasehold Improvements | 41.95 | 51.47 | 39.47 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.